Newsletter

Healthcare Stocks

Here Are 5 ASX Stocks Pro Medicus Could Buy Next And If They Even Make Sense

What ASX Stocks Pro Medicus Could Buy Next? Pro Medicus (ASX:PME) has never been a serial acquirer since it picked up Visage at a bargain price during the GFC. But is it turning into one? It invested in 4D Medical (ASX:4DX) last July and yesterday it chipped into EchoIQ. So what next? We can only speculate…

ByNick SundichJune 26, 2026

Imagion Biosystems (ASX:IBX) raises A$3.75m at a 24% discount to start dosing

Imagion Biosystems (ASX:IBX) raised A$3.75m at a 24% discount to fund the start of its MagSense HER2 Phase 1b/2 trial in the US.

ByCharlie YouldenJune 25, 2026

Pro Medicus (ASX:PME) writes a A$20m cheque into Echo IQ

Pro Medicus (ASX:PME) commits up to A$20m to Echo IQ via secured convertible notes and becomes US reseller of EchoSolv, signalling a platform shift.

ByCharlie YouldenJune 25, 2026

This Phase 2 ASX Biotech Has a Drug That Is One of Its Kind and Has Been Progressing Nicely!

Phase 2 ASX Biotech Prescient Therapeutics (ASX:PTX) has spent the better part of a decade building up to the point it is at now. 2026 has become the year in which the investment case is finally coming into focus. PTX‑100 is the world’s first GGTase‑1 inhibitor to enter human trials, and it remains the only…

ByNick SundichJune 25, 2026

ECS Botanics (ASX:ECS) launches 23% THC Gelonoidz #20 as premium pivot lands

ECS Botanics (ASX:ECS) launches Gelonoidz #20, its first Australian-grown Terphogz product, marking a premium pivot with up to three cultivars due in FY27.

ByCharlie YouldenJune 22, 2026

Cynata (ASX:CYP) Phase 3 knee trial misses and Cymerus is now under review

Cynata Therapeutics (ASX:CYP) Phase 3 knee osteoarthritis trial missed both endpoints, triggering a review of the entire Cymerus platform.

ByCharlie YouldenJune 19, 2026

BCAL Diagnostics (ASX:BDX) BREASTEST Monitor flags 91% sensitivity in early recurrence read

BCAL Diagnostics (ASX:BDX) unveiled BREASTEST Monitor, a blood test for breast cancer recurrence with 91% sensitivity in early validation data.

ByCharlie YouldenJune 18, 2026

Intuitive Surgical (NDQ:ISRG): This robotic surgery pioneer has faced plenty of headwinds in 2026!

Intuitive Surgical (NDQ:ISRG) is one of the most important companies in modern medical technology. It pioneered robotic‑assisted surgery, built a global installed base that competitors have spent decades trying to replicate, and created one of the most durable recurring‑revenue machines in healthcare. But this does not mean it has been immune from challenges and has…

ByNick SundichJune 18, 2026

TALi Digital (ASX:TD1) hands audit chair to a Suubee founder

TALi Digital (ASX:TD1) has appointed Suubee founder George Rolleston as Audit Chair, signalling a likely shift in capital and M&A strategy.

ByCharlie YouldenJune 16, 2026

Sigma Healthcare (ASX:SIG) walks away from Boots and the UK plan just got smaller

Sigma Healthcare (ASX:SIG) has walked away from the Boots sale process, signalling capital discipline and shifting its UK growth onto the smaller Greenlight MoU.

ByCharlie YouldenJune 15, 2026